Cargando…

Identification of the risks in CAR T-cell therapy clinical trials in China: a Delphi study

AIMS: Within the past few years, there has been tremendous growth in clinical trials of chimeric antigen receptor (CAR) T-cell therapies. Unlike those of many small-molecule pharmaceuticals, CAR T-cell therapy clinical trials are fraught with risks due to the use of live cell products. The aim of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Weijia, Huo, Yan, Ding, Xueying, Zhou, Yuhong, Gu, Shengying, Gao, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580145/
https://www.ncbi.nlm.nih.gov/pubmed/33149770
http://dx.doi.org/10.1177/1758835920966574